The people behind the ideas.
The ideas behind the companies.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. The company has developed a proprietary platform technology, called AlphaSeq, that uses genetically engineered cells to experimentally measure millions of protein-protein interaction affinities simultaneously at a library-on-library scale, generating enormous amounts of data to inform the discovery and development of the next generation of high-impact therapeutics. A-Alpha Bio was founded in 2017 by a team of synthetic biologists from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.

Envisagenics is an Artificial Intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing events that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders.

Modulus Therapeutics is a seed-stage cell therapy design studio developing an internal pipeline of NK cell anti-solid tumor programs. Failures in cell therapy efficacy can be traced to poor conceptualization, design and integration of engineered components. Modulus is uniting whole-cell synthetic biology with machine learning into a cell therapy design solution to dramatically reduce pipeline risk and accelerate the path to the clinic. The team is a diverse group of cell therapy veterans along with bioengineering and machine learning experts laser focused on driving therapeutic efficacy by accessing the full cell design space.

Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Ovation is a next-generation clinical informatics company.

Ozette Technologies, Inc. is engineering a transformative leap in cell discovery and annotation of the human immune system. The Seattle-based (remote-first) life sciences technology startup is building a groundbreaking high-resolution, intelligent, single-cell immune monitoring platform and corpus of high-resolution data leveraging its novel AI technologies. Founded in late 2020, Ozette was spun-out from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. Ozette’s interdisciplinary team is made up of a deep bench of scientists, engineers, and designers with a wide range of experience spanning Genentech, Google, Microsoft, Amazon, Airbnb, and leaders and pioneers in the field of medical research and single cell analysis.

Proof is a startup working to make powerful CRISPR-based molecular testing affordable and accessible to everyone

Terray Therapeutics is an emerging biotechnology company led by pioneers and long-time leaders in AI, medicinal chemistry, biology and preclinical development, automation, and nanotechnology to propel drug discovery into the information age. Terray’s proprietary integrated computational and experimental platforms generate massively scaled, powerfully agnostic chemical data that are purpose-built to power computational learning and reveal new interactions. This foundation is building an iterative, flexible chemistry engine that aims to deliver more precise therapies to patients faster than ever before.

TwinStrand Biosciences is a Seattle genomics company building a platform around Duplex Sequencing, a proprietary process that helps physicians, patients and drug researchers make life saving decisions faster based on DNA data.